Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales

theglobeandmail.com/business/article-johnson-johnson-profit-darzalex-medtech

Johnson & Johnson JNJ-N raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on strong demand for its cancer drug, Darzalex, and strength in its medical device business.
The company also reduced its expectations for tariff-related costs to…

This story appeared on theglobeandmail.com, 2025-07-16 11:12:56.
The Entire Business World on a Single Page. Free to Use →